Allergy Symptoms (itchy eyes, nasal congestion, sneezing), Asthma, Rhinitis
Patient Specific Allergens (Inhalants (Dust Mites, Cat, Dog, etc.), Pollens (Trees, Grasses, Weeds), Moulds) suspended in 50% glycerin…1:100v/v
This formula is designed to increase the immunity of patient specific allergens. The extra strength concentration will be used for maintenance.
Sublingual Immunotherapy (SLIT) is an alternative way to treat allergies without injections and is well-suited to the needle phobic, children, travelers and the elderly. An allergist gives a patient very small doses of an allergen sublingually to boost tolerance to the substance and reduce symptoms.
Currently, the only forms of SLIT approved by the US FDA are tablets for ragweed and grass pollen. The safety and efficacy of sublingual allergy liquid solutions are still being established by the FDA, and they are only used off-label in the United States. In Canada, off-label SLIT is commonly used in naturopathic medical practice and this form of therapy is being quickly accepted by traditional allopathic medical doctors.
2-4 drops per day (each drop is 0.05mL)
The most common reaction is itching in the mouth. This may happen immediately or several hours after the treatment and may last up to 24 hours. In some cases especially in the Build-up Phase, symptoms may include increased allergy reactions such as sneezing or nasal congestion. These local reactions at injection sites and transient increases in symptoms during the Build-up Phase are not considered serious.
Serious reactions to SLIT are extremely rare. When they do occur, they require immediate medical attention. Symptoms of an anaphylactic reaction can include swelling in the throat, wheezing or tightness in the chest, nausea and dizziness. Most serious reactions develop within 30 minutes of the allergy treatment. For some high risk patients such as those with a history of severe asthma, or previous severe non-anaphylactic reactions to immunotherapy, it may be necessary to have an Epipen® at home.
Do not take with Beta Blockers
Current Status of Sublingual Immunotherapy in the U.S., Michael S. Blaiss, MD Clinical Professor of Pediatrics and Medicine University of Tennessee Health Science Center Memphis, Tennessee
Disclaimer: This content is subject to change. The information is intended to inform and educate; it does not replace the medical evaluation, advice, diagnosis or treatment by a healthcare professional. www.nhpassist.com © 2014 NDAssist Inc. and/or its affiliates. All rights reserved.